Summary
Elevance Health Posts $2B Profit in Q1 of 2023
In this episode, we are joined by regular guest Jakob Emerson, Insurance Editor at Becker’s Healthcare to discuss Elevance Health posting a $2B profit in Q1 of 2023 and what UnitedHealth Group is saying about the coverage of GLP-1 drugs, such as Ozempic for weight loss.
Jakob Emerson
Jacob Emerson is the associate news director at Becker’s Healthcare and he is currently following two stories in the healthcare space.
Elvas Health’s First Quarter Earnings
The first story is Elvas Health’s first quarter earnings which saw double digit revenue growth. This is exciting news for the healthcare industry as it shows that companies in the space are able to thrive during difficult economic times.
UnitedHealth Group’s Take on GLP-1 Drugs
The second story follows United Health Group’s take on the new class of expensive obesity and diabetes prescriptions, which they say is mostly being used for diabetic care with low single digits for weight loss. This is an interesting perspective considering the growing obesity epidemic and the potential impact these drugs could have on weight loss and overall health.
Note: This is an AI generated transcript, not edited by a staff writer and is solely intended for educational purposes. If you have any questions/concerns, reach out to podcasts@beckershealthcare.com
This episode aired on 04/20/2023 and can be listened here.
Subscribe to Beckers Healthcare Podcast here.